NCT06785779

Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 77 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.

Detailed description

This is a 24-week longitudinal single arm prospective study based on data collected from electronic medical records (EMRs) and patient-reported outcomes questionnaires (TSQM, DLQI, and NPRS-11) to evaluate patient-reported satisfaction and early QoL experiences among HS adult patients who are newly administering Secukinumab as per routine clinical practice. Data will be captured from both data sources (EMRs and Questionnaires) at the following time points (+/- 1 month): * Baseline (index date: initiation of Secukinumab), * 24 weeks. This is in line with the frequency of routine follow-up visits and as per the standard of care to report on pre-defined outcomes in a representative HS population across Saudi Arabia.

Conditions

• Hidradenitis Suppurativa (HS)

Interventions

Type	Name	Description
OTHER	Secukinmab	This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Timeline

• Start date: 2025-03-10
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2025-01-21
• Last updated: 2025-12-30

Locations

4 sites across 1 country: Saudi Arabia